Lion Biotechnologies to Present at the LD MICRO Co
Post# of 94266
Posted On: 11/26/2013 8:09:45 AM
Lion Biotechnologies to Present at the LD MICRO Conference on December 3
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.
Mr. Handelman will be available for one-on-one meetings with the investment community during the conference. Please contact LD Micro organizers if you would like to arrange a meeting.
About Lion Biotechnologies
Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.genesis-biopharma.com/.
INVESTOR CONTACT:
LHA
Don Markley
Senior Vice President
310-691-7100
dmarkley@lhai.com
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.
Mr. Handelman will be available for one-on-one meetings with the investment community during the conference. Please contact LD Micro organizers if you would like to arrange a meeting.
About Lion Biotechnologies
Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.genesis-biopharma.com/.
INVESTOR CONTACT:
LHA
Don Markley
Senior Vice President
310-691-7100
dmarkley@lhai.com
(0)
(0)